USPSTF: Evidence Lacking for Screening for Speech Delays in Young Children
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
TUESDAY, July 25, 2023 -- The evidence is insufficient for assessing the balance and harms of screening for speech and language delay and disorders in young children. These findings form the basis of a draft recommendation statement published online July 25 by the U.S. Preventive Services Task Force (USPSTF).
Cynthia Feltner, M.D., M.P.H., from RTI International-University of North Carolina at Chapel Hill Evidence-based Practice Center in Research Triangle Park, and colleagues conducted a systematic review of the evidence on screening for speech and language delay or disorders in children aged 5 years or younger. A total of 38 studies were reported in 41 articles, including 9,006 participants. The researchers found that none of the studies evaluated the direct benefits of screening versus no screening. In 21 studies, the accuracy of 23 instruments for detecting speech and language disorders was assessed. Across included studies, the sensitivity and specificity varied widely. None of the studies reported on the benefits and harms of screening versus no screening or on potential harms of interventions. The enrolled populations were heterogeneous, as were the specific type of speech and language disorders targeted.
Based on these findings, the USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of speech and language delay and disorder screening in children (I statement). The statement applies to asymptomatic children aged 5 years or younger whose parents or clinicians do not have specific concerns relating to speech or language.
The draft recommendation statement and evidence review is posted for public comment. Comments can be submitted from July 25 through Aug. 21, 2023.
Draft Recommendation Statement
Comment on Recommendation Statement
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted July 2023
Read this next
AI-Assisted Contours Superior to Cognitively Defined Prostate Cancer Contours
WEDNESDAY, July 3, 2024 -- Artificial intelligence (AI)-assisted definition of prostate cancer contours reduces underestimation of the extent of prostate cancer, according to a...
Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million
TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...
Patient–Primary Care Provider Language Concordance Tied to Better Outcomes
TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.